114 related articles for article (PubMed ID: 33339730)
1. A Breast Radiology Department-operated, Proactive Same-day Program Identifies Pathogenic Breast Cancer Mutations in Unaffected Women.
Loving VA; Luiten RC; Siettmann JM; Mina LA
Acad Radiol; 2022 Jan; 29 Suppl 1():S239-S245. PubMed ID: 33339730
[TBL] [Abstract][Full Text] [Related]
2. Universal Genetic Testing for All Breast Cancer Patients.
Copur MS
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469901
[TBL] [Abstract][Full Text] [Related]
3. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
[TBL] [Abstract][Full Text] [Related]
4. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
5. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
Ozanne EM; Howe R; Mallinson D; Esserman L; Van't Veer LJ; Kaplan CP
J Genet Couns; 2019 Jun; 28(3):507-515. PubMed ID: 30663827
[TBL] [Abstract][Full Text] [Related]
7. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a risk assessment program in a breast-imaging community practice.
Destounis S; Arieno A; Morgan R
Breast Cancer; 2016 Mar; 23(2):273-8. PubMed ID: 25287518
[TBL] [Abstract][Full Text] [Related]
9. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
10. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
11. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
[TBL] [Abstract][Full Text] [Related]
12. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.
Mittal A; Deo SVS; Gogia A; Batra A; Kumar A; Bhoriwal S; Deb KS; Dhamija E; Thulkar S; Ramprasad VL; Olopade O; Pramanik R
Ann Surg Oncol; 2022 Feb; 29(2):1423-1432. PubMed ID: 34601666
[TBL] [Abstract][Full Text] [Related]
13. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
14. Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario.
Vanstone M; Chow W; Lester L; Ainsworth P; Nisker J; Brackstone M
Can Fam Physician; 2012 May; 58(5):e258-66. PubMed ID: 22734169
[TBL] [Abstract][Full Text] [Related]
15. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
16. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
17. Testing for hereditary breast and ovarian cancer in the southeastern United States.
Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
[TBL] [Abstract][Full Text] [Related]
18. Population-based genetic testing for Women's cancer prevention.
Evans O; Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():139-153. PubMed ID: 32245629
[TBL] [Abstract][Full Text] [Related]
19. Participation in breast cancer susceptibility testing protocols: influence of recruitment source, altruism, and family involvement on women's decisions.
Geller G; Doksum T; Bernhardt BA; Metz SA
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 2):377-83. PubMed ID: 10207643
[TBL] [Abstract][Full Text] [Related]
20. A Community Health Worker Model to Support Hereditary Cancer Risk Assessment and Genetic Testing.
Marsh L; Mendoza M; Tatsugawa Z; Pineda E; Markovic D; Holschneider CH; Zakhour M
Obstet Gynecol; 2023 Sep; 142(3):699-707. PubMed ID: 37535963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
